The mission of the Tufts Health Care Institute Program on Opioid Risk Management is to address challenges in the development and utilization of opioid analgesics, by engaging a multidisciplinary group of stakeholders focused on optimizing the benefits of opioid for pain management, and minimizing their risks, including abuse and diversion.

June 26 & 27, 2008

Executive Summary

June 2008

Agenda

A Brief History of Urine Drug Testing: Forging a Common Vocabulary
Gary Reisfield, MD , Presentation >>

Opioid Pharmacology and Urine Drug Monitoring
J. David Haddox, DDS, MD, Presentation >>

Pharmacokinetics and Disposition of Urine Drug Monitoring: Comparison of Various Sources for Drug Testing: Urine, Blood, Hair, Saliva
Edward Cone, PhD, Presentation >>

Analytical Methods Used in Urine Drug Monitoring
Judith Stone, PhD, Presentation >>

Ways to Deceive Drug Testing
Ted Shults, Presentation >>

A Review of Outcome Studies and Gaps in the Literature of Urine Drug Monitoring
Joanna Starrels, MD, Presentation >>

Initiatives to Develop Professional Standards for Urine Drug Monitoring
Roger Bertholf, PhD, Presentation >>

Clinical Applications of Urine Drug Monitoring in the Addiction Treatment Setting
John Femino, MD, MS, Presentation >>

Clinical Applications of Urine Drug Monitoring in the Pain Management Setting: Proposed Guidelines
Howard Heit, MD, Presentation >>

Urine Drug Monitoring: Payer Perspectives
Annette Hanson, MD, MBA, Presentation >>

Case Studies in UDM in Paine Management: Handling Problem Patients
Doug Gourlay, MD, Presentation >>

Concurrent Workgroup Breakouts

Breakout Group 1: Guidelines for the use of (Urine) Drug Monitoring in Pain Management Presentation >>

Breakout Group 2: Clinical Research Gaps Related to Urine Drug Monitoring
Presentation >>

Breakout Group 3: Ethical issues Presentation >>